Tardastrex (Delmadinone Acetate) is a compound used primarily in male dogs and cats to manage specific conditions and symptoms that are driven by the biological effects of androgens. Its use is centered on providing relief and stability in contexts of excessive hormonal activity.

The compound is commonly used to help with conditions characterized by periods of heightened symptoms, including Benign Prostatic Hyperplasia (BPH), excessive sexual behavior (hypersexuality), and certain forms of hormone-related aggression and chronic itching (pruritus).

Quick Fact: Relief for Androgen-Driven Symptoms

Therapeutic Focus	Symptom Axis	Benefit
Prostate	Straining during urination	Assists with maintaining functional stability
Behavior	Excessive sexual activity	Supports a more stable behavioral experience
Dermatology	Resistant chronic itching	Contributes to easing the overall symptom load

The therapeutic benefit is relevant for easing symptoms that result from the temporary effect on prostate volume, and it may help provide supportive relief that assists with maintaining a more stable behavioral experience. The primary goal is symptom management by addressing the underlying hormonal influence, which supports general well-being during symptomatic phases. This approach contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) Product Summary

Tardastrex (Delmadinone acetate) is officially indicated for use only in male dogs and male cats. Regulatory documents establish strict population eligibility rules based on the animal's age, organ health, and existing comorbidities.

Population Status	Official Regulatory Statement
Absolute Contraindication	The medicine must not be used in animals with Diabetes Mellitus, Mammary Tumors, or severe impairment of liver or kidney function.
Age Restriction	Use is strictly contraindicated in male dogs under one year of age, as established in regulatory labeling.
Concomitant Therapy	Use is contraindicated in animals receiving long-term glucocorticoids or in dogs already being treated with progestogens.
Route Restriction	The product is restricted to intramuscular or subcutaneous injection; intravenous administration is contraindicated.

Special Population Restrictions: Specific caution is required for breeding animals, as the medicine may cause reduced fertility and reduced libido, with an unpredictable time required for the return of normal function. Furthermore, the medicine should only be used with great care if the animal is concurrently receiving other steroid compounds.

The official regulatory profile for Tardastrex (Delmadinone Acetate) is defined by its formally documented interactions with hormonal therapies and substances that influence metabolic enzyme activity. These documented interaction patterns establish the necessary restrictions and cautions for co-administration.

---

Interaction Scope

Category	Product or Substance
Medicinal product categories with documented interactions	Glucocorticoids, Progestogens, Enzyme Inducers, Other steroid compounds
Specific interacting medicines (if explicitly listed)	Carbamazepine, Phenobarbital, Rifampicin
Mechanistic basis of interactions	Reduction of progestogenic effect via enzyme induction; additive pharmacological effect with other steroid compounds
Population-specific interaction notes	Reduces sensitivity to insulin

---

Interaction-Related Restrictions and Classifications

Classification	Official Regulatory Constraint
Contraindicated Combinations	Co-administration with other progestogens is strictly prohibited. Use is also formally contraindicated with glucocorticoids when prescribed for long-term therapy.
Exposure-Modifying Interaction	Concomitant use with strong enzyme inducers (such as Carbamazepine, Phenobarbital, or Rifampicin) may result in a reduced effect of the progestogenic substance.
Caution Required	The product must be handled with great care when animals are receiving treatment involving other steroid compounds.

The official labeling classifies the use of Tardastrex with certain hormonal agents as contraindicated, which is the highest level of regulatory restriction. This hormonal interaction and the documented risk of reduced efficacy due to metabolic enzyme induction structure the drug's interaction profile. No mandatory timing-based separation rules or documented interactions with food, alcohol, or herbal products are specified in the official regulatory documentation. The final constraint involves its documented ability to reduce sensitivity to insulin, which is a key consideration for specific patient populations.

Tardastrex, which contains delmadinone acetate (DMA), functions as a synthetic steroid derivative with a complex pharmacodynamic profile encompassing antiandrogenic, progestogenic, and antigonadotropic actions.

Molecular and Cellular Targets

DMA acts primarily as a competitive antagonist at the androgen receptor (AR) in target tissues, including the prostate and perianal glands, thereby preventing the binding and subsequent cellular action of endogenous androgens such as testosterone and dihydrotestosterone (DHT). Furthermore, DMA is an inhibitor of the enzyme 5alpha-reductase, which catalyzes the conversion of testosterone to the more potent DHT. This dual mechanism reduces the effective androgen signaling cascade.

Downstream Cascades and System Effects

Its progestogenic activity exerts an antigonadotropic effect by modulating the hypothalamic-pituitary-gonadal (HPG) axis. Specifically, DMA decreases the secretion of gonadotropins from the pituitary gland. This reduction in gonadotropin levels leads to a subsequent decrease in testosterone production by the testes, resulting in a systemic reduction of circulating androgens. The cumulative effect of AR antagonism, 5alpha-reductase inhibition, and reduced testosterone synthesis is an overall modulation of androgen-dependent cellular proliferation and physiological processes.

How Tardastrex is Used: Official Administration Guidelines

Tardastrex (Delmadinone Acetate) is officially administered as a single injection of an aqueous suspension containing 10 mg/ml of the active substance. The only approved methods are intramuscular (IM) injection or subcutaneous (SC) injection. The container must be shaken thoroughly before use to ensure the suspension is homogeneous for correct administration.

---

Dosage and Schedule

The dosage is not uniform but is weight-dependent, with regimens established for different body weights in male dogs. The dose for large dogs (20 kg and above) is 1.0 mg/kg, while smaller dogs (under 10 kg) require a higher range of 1.5 to 2.0 mg/kg. The official instructions require that the maximum recommended dose not be exceeded.

As the medicine is formulated as a depot preparation, it provides a sustained effect, structuring the treatment as an intermittent schedule. Follow-up treatments are typically considered after a period of three to four weeks in animals that have responded favorably. If no improvement is observed within eight days of the initial injection, a second dose, at least equal to the first, may be considered.

Research Evidence / Overview of Studies for Tardastrex

This section provides an overview of the official research and studies conducted for Delmadinone acetate, focusing only on the structure of the evidence and what has been explored by researchers, without offering clinical advice or making claims about individual outcomes.

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH)

Delmadinone acetate was studied for BPH, a condition characterized by functional imbalance, primarily utilizing Randomized Controlled Trials (RCTs) and non-comparative clinical studies. Research examined the measurement of Prostate Volume (PV) and the scoring of specific BPH-related clinical signs, such as straining during urination. Data show patterns related to specific sex hormone biomarkers measured during the study period. Follow-up durations were limited in some comparative trials, meaning long-term effects are not fully established regarding the symptom patterns over extended periods. Results apply only to the specific older male populations studied.

---

Evidence for Use in Excessive Sexual Behavior (Hypersexuality)

Delmadinone acetate was studied for research contexts involving fluctuating or unstable symptoms, specifically for excessive sexual behaviors. Studies explored the measured rate of change in behavior and the duration of the stable period following treatment. Findings describe patterns observed during the study period, including instances of extended stable periods. Regulatory summaries indicate that the response may be variable across individual subjects. The certainty remains low for predicting personal outcomes, as initial studies relied heavily on owner-reported outcomes.

---

Key Limitations and Areas of Research Uncertainty

Across various studies, the sample sizes were small, especially for behavioral or dermatological indications, meaning that findings describe group patterns, not personal outcomes. Follow-up durations were limited in several pivotal trials, contributing to the uncertainty regarding long-term outcomes. The evidence quality varies across studies, and regulatory summaries explicitly noted that findings were mixed, suggesting that response can be variable. Comparative evidence against the full range of alternative treatments is lacking for some uses.

Key Studies & References Tardastrex 10 mg/ml Suspension for Injection for Dogs and Cats - Veterinary Medicines Directorate (UKPAR)

Common questions about Tardastrex (FAQ)

Q: How quickly does Tardastrex start to work after the first dose?

Official documents note that an immediate effect should not be expected after the initial administration. In most cases, two to four days may elapse before the effect of treatment is observed, as described in the regulatory prescribing information.

Q: What are the most commonly reported side effects of Tardastrex?

According to official product information, the effects reported as 'occasionally seen' include increased appetite, excessive thirst (polydipsia), and excessive urination (polyuria). These effects are generally described as transient, meaning they are temporary.

Q: Why is my doctor asking me to have regular blood tests while on Tardastrex?

Regulatory information describes the potential for elevated plasma liver enzymes and the manifestation of latent diabetes mellitus. These documented changes are often assessed through regular monitoring to confirm stability.

Q: What does the patient leaflet for Tardastrex say about discontinuing use?

Regulatory information states that the substance may cause adrenal suppression, which can result in a risk of adrenocortical insufficiency when the subject is under stress. For breeding subjects, the return of normal reproductive function after treatment is noted as unpredictable.

Q: Can I drive a car while using Tardastrex?

Tardastrex is a veterinary medicine intended for use in animals, not humans. For human handlers, official warnings state that preparations containing progestogens should be handled with care, particularly by women of childbearing age. Contact with the skin should be avoided during administration.

Q: Does Tardastrex have a long-term effect after I stop using it?

The time to return of normal reproductive function in breeding animals is noted as unpredictable in regulatory documents. Studies related to the treatment's effect have not fully established the long-term patterns regarding symptoms over extended periods.

Q: Are there any major diet restrictions when using Tardastrex?

Official regulatory documentation does not specify any mandatory restrictions with food or major dietary rules. However, because an increase in appetite is a documented side effect, official guidance suggests managing food intake as a measure to prevent an increase in bodyweight.

Q: Is it okay to have alcohol while taking Tardastrex?

Regulatory documents related to the medicine's interaction profile do not specify any documented interactions with alcohol.

Q: Does Tardastrex cause weight gain or weight loss?

An increase in appetite is listed in the official documents as an 'occasionally seen' side effect. The regulatory information suggests that controlling food intake may be a factor in preventing an increase in bodyweight.

Q: Is hair loss a possible side effect of Tardastrex?

Official documentation lists local changes in the hair coat as documented adverse reactions. These changes may include lightening of color and/or hair loss.

Q: Can taking Tardastrex affect the results of any lab tests?

Official information indicates the drug has documented effects on certain metabolic markers that are measured by lab tests. These include the possibility of elevated plasma liver enzymes and changes that may lead to the manifestation of latent diabetes mellitus.

Q: Is it normal to feel a bit nauseous when starting Tardastrex?

In rare cases, the regulatory product information has reported 'transient digestive disorders.' These digestive issues may include symptoms such as nausea.

Q: Is Tardastrex safe to use during pregnancy, based on regulatory information?

Regulatory information indicates that the medicine is officially contraindicated in pregnant subjects, as it is a hormonal compound. Official documents note that use in pregnant females may cause fetal developmental defects.

Q: Can I breastfeed while using Tardastrex?

The official product document includes a section concerning use during pregnancy and lactation. However, it does not contain a specific prohibition or instruction regarding use during lactation.

Q: What happens if I stop taking Tardastrex suddenly?

Regulatory documents state that the medication may cause adrenal suppression, which is the decreased function of the adrenal glands. This is linked to a risk of developing adrenocortical insufficiency during or after treatment when the subject is under stress.

Q: Is it possible for Tardastrex to stop working after a while?

Official regulatory summaries explicitly note that the response to the treatment may be variable across individual subjects. Study results indicate that treatment response is not guaranteed and can vary.

Q: What are the signs of a serious side effect from Tardastrex that requires urgent attention?

Official documents describe serious documented effects such as adrenal suppression and the manifestation of latent diabetes mellitus. The product label also indicates that if commonly reported effects, such as increased appetite, excessive thirst, or excessive urination, become severe or excessive, the substance should be discontinued.

Q: Can I take vitamins while using Tardastrex?

Official regulatory documentation does not specify any documented interactions with food, alcohol, or herbal products. The regulatory label does not list any specific interactions with vitamins.

The official regulatory documents specify strict conditions for the storage and disposal of Tardastrex (Delmadinone Acetate) to maintain product integrity and safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Do not store the product above 25°C (77°F).
Protection	Must be stored in the outer carton to protect from light.
Handling	The suspension must be shaken before use. Preparations containing progestogens should be handled with care, particularly by women of childbearing age.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The shelf-life after the vial is first opened is 28 days; any product remaining after this period must be discarded. Disposal of any unused product or waste materials must be carried out in accordance with local requirements for medicinal products.